Cathie Wood’s ARK Invest made several portfolio moves on January 22, 2026, according to the fund’s daily trading disclosure. The investment firm sold more than $5 million in biotech stock while adding to positions in autonomous driving and healthcare AI companies.
The biggest trade of the day involved Beam Therapeutics. ARK sold 161,683 shares across two ETFs for a total value of $5.03 million. The shares were distributed between the ARK Innovation ETF and the ARK Genomic Revolution ETF.
This sale continues a trend from earlier in the week. ARK has been reducing its Beam Therapeutics position over multiple trading sessions. The approach suggests a gradual exit rather than a complete dump of the stock.
ARK added 166,029 shares of WeRide through the ARK Autonomous Technology & Robotics ETF. The purchase totaled $1.47 million. WeRide is a Chinese company focused on self-driving vehicle technology.
The WeRide purchase follows a pattern of consistent buying. ARK has accumulated shares in the autonomous driving firm throughout the week. The repeated purchases indicate growing conviction in the company’s prospects.
Tempus AI also received fresh capital from ARK. The fund bought 13,532 shares for $884,000 across its ARKK and ARKG ETFs. Tempus AI operates a data-driven platform for healthcare applications.
This marks another round of investment in Tempus AI. ARK has shown repeated interest in the company over recent trading sessions.
ARK reduced holdings in several software companies during the session. Unity Software saw a sale of 32,227 shares through the ARK Next Generation Internet ETF. The transaction totaled $1.35 million.
Roku experienced selling as well. ARK offloaded 14,885 shares of the streaming platform for $1.55 million. The sale continues a broader pattern of portfolio adjustment in media stocks.
GitLab faced another round of selling from ARK. The fund sold 29,533 shares valued at $979,000. This extends a pattern of reducing exposure to the software development platform.
Kratos Defense and Security Solutions also saw selling. ARK dumped 2,631 shares across three different ETFs. The total value reached $317,000.
The fund made one small additional purchase beyond WeRide and Tempus AI. ARK bought 7,175 shares of Kodiak AI for $66,000 through the ARKQ ETF. The purchase represents a minor addition to the portfolio.
The trading activity shows ARK’s strategy of rotating out of biotech and traditional software stocks. The fund appears to be concentrating capital in autonomous driving and AI-focused healthcare companies instead.
The post Cathie Wood Sells Beam Therapeutics Stock, Buys WeRide and Tempus AI appeared first on Blockonomi.
Also read: Intel (INTC) Stock: Why Shares Crashed 13% After Earnings Despite Revenue Win
